# Burning Rock Biotech Ltd (BNR)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/burning-rock-biotech-ltd/ JSON: https://steadybase.io/company/burning-rock-biotech-ltd.json Checked Nov 21, 2026. Latest filing read: Apr 28, 2026.

## Company

- Legal name: Burning Rock Biotech Ltd
- Ticker: BNR (Nasdaq)
- SEC CIK: 0001792267
- Industry: Services-Medical Laboratories (SIC 8071)
- Headquarters: Guangzhou, Guangdong
- SEC filer category: Non-accelerated filer
- Website: brbiotech.com
- LinkedIn: https://www.linkedin.com/company/burning-rock-biotech
- Next earnings date: Nov 19, 2026

## Key facts

- Revenue: $77.2M for the fiscal year ended Dec 31, 2025 (20-F filed Apr 28, 2026). Source: https://www.sec.gov/Archives/edgar/data/1792267/000119312526183377/0001193125-26-183377-index.html
- Operating income: -$7.8M for the fiscal year ended Dec 31, 2025 (20-F filed Apr 28, 2026). Source: https://www.sec.gov/Archives/edgar/data/1792267/000119312526183377/0001193125-26-183377-index.html
- Net income: -$7.9M for the fiscal year ended Dec 31, 2025 (20-F filed Apr 28, 2026). Source: https://www.sec.gov/Archives/edgar/data/1792267/000119312526183377/0001193125-26-183377-index.html
- SG&A: $41.7M for the fiscal year ended Dec 31, 2025 (20-F filed Apr 28, 2026). Source: https://www.sec.gov/Archives/edgar/data/1792267/000119312526183377/0001193125-26-183377-index.html
- Auditor: Ernst & Young Hua Ming LLP, Shanghai, the People’s Republic of China, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1792267/000119312526183377/d31568d20f.htm

## Business

We aim to transform precision oncology and early cancer detection. We are China’s leading NGS-based cancer therapy selection company. Our cancer therapy selection platform is built upon our advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1792267/000119312526183377/d31568d20f.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $77.2M | -$7.8M | -$7.9M | $41.7M |
| Dec 31, 2024 | $70.7M | -$49.0M | -$47.5M | $62.0M |
| Dec 31, 2023 | $75.7M | -$94.3M | -$92.1M | $96.6M |
| Dec 31, 2022 | $81.7M | -$142.1M | -$140.8M | $136.1M |
| Dec 31, 2021 | $79.7M | -$125.1M | -$125.0M | $124.5M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/burning-rock-biotech-ltd.json

## Officers and directors

- Xiaozhi Hu, Senior Director in Finance. Source: Form 3 filed Mar 17, 2026, https://www.sec.gov/Archives/edgar/data/1792267/000119312526109641/0001193125-26-109641-index.htm

## Insider trades (Form 4)

- Jun 26, 2026: Yusheng Han (Director) bought 731,410 shares, about $6.2M. Source: https://www.sec.gov/Archives/edgar/data/1792267/000119312526293511/0001193125-26-293511-index.htm
- Mar 31, 2026: Yusheng Han (Director) bought 314,870 shares, about $5.5M. Source: https://www.sec.gov/Archives/edgar/data/1792267/000119312526138961/0001193125-26-138961-index.htm

## Latest filings

- 20f filed Apr 28, 2026: https://www.sec.gov/Archives/edgar/data/1792267/000119312526183377/d31568d20f.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

